MHRA Grants New Indication for argenx’s Vyvgart in Chronic Inflammatory Demyelinating Polyneuropathy

As reported by The Pharma Letter, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a new indication for argenx’s Vyvgart (efgartigimod alfa), expanding the therapy’s use to…

Continue Reading MHRA Grants New Indication for argenx’s Vyvgart in Chronic Inflammatory Demyelinating Polyneuropathy